Is raloxifene a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro?
The in vitro antioxidant activity of RLX is substantially more potent than TMX or E2. This finding, added to the other beneficial effects of the drug in the cardiovascular system, could imply some cardioprotector effect.
The final PS model within the Austrian PHE is based on a wealth of data justifying an evidence-based intervention. The Austrian population is likely to benefit in many ways from the intervention through increased awareness of PD and through a collaboration of medical and dental clinicians in their prevention.